Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer

Abstract

Pegylated liposomal doxorubicin (PLD) has become a major component in the routine management of epithelial ovarian cancer. The drug is frequently employed as a single agent in the platinum-resistant setting, and recently reported data reveal the superiority of the combination of PLD plus carboplatin, compared with the platinum drug plus paclitaxel, in delaying the time to disease progression in women with recurrent (potentially platinum-sensitive) disease. Current research efforts involving PLD in ovarian cancer are focusing on adding novel targeted drugs to this cytotoxic agent. The utility of such approaches in the platinum-resistant population, compared with the sequential administration of single agents active in this setting, remains to be determined.

Keywords:

• PLD
• carboplatin
• paclitaxel
• platinum-sensitive
• platinum-resistant

Disclosure

The author reports no conflicts of interest in this work.